In the modern landscape of infectious disease management, antiviral therapies have revolutionized the treatment of chronic viral infections such as HIV-1 and Hepatitis B. Among the most widely recognized and clinically validated antiviral agents is Tenofovir Disoproxil Fumarate, a key component of many global treatment guidelines. TELAVINCE 300, a premium formulation of Tenofovir Disoproxil Fumarate 300 mg, is designed to deliver effective, consistent, and safe antiviral therapy for patients living with HIV and chronic Hepatitis B.
Manufactured under stringent quality control by leading pharmaceutical professionals, TELAVINCE 300 stands out for its reliability, therapeutic efficacy, and cost-effectiveness, making it a preferred choice for healthcare providers and patients alike.
What is TELAVINCE 300?
TELAVINCE 300 is a once-daily oral antiviral medication containing Tenofovir Disoproxil Fumarate (TDF) 300 mg, classified under nucleotide reverse transcriptase inhibitors (NtRTIs). This medication is used in the treatment of:
HIV-1 infection, in combination with other antiretroviral drugs
Chronic Hepatitis B (HBV) infection in adults and adolescents
It functions by interfering with the viral replication process, reducing the viral load in the body, and helping to restore or maintain immune function.
Mechanism of Action
Tenofovir Disoproxil Fumarate is a prodrug that is rapidly converted in the body to tenofovir, an active metabolite. Tenofovir is phosphorylated to tenofovir diphosphate, which inhibits the activity of reverse transcriptase enzymes—critical enzymes for the replication of HIV and Hepatitis B viruses. This inhibition results in premature termination of the viral DNA chain, preventing the virus from multiplying and spreading.
This mechanism makes TELAVINCE 300 effective at suppressing viral load, slowing disease progression, and reducing the risk of transmission.
Indications and Usage
TELAVINCE 300 is indicated for the following:
1. HIV-1 Infection
Used as part of a combination antiretroviral therapy (ART) regimen
Helps to achieve and maintain undetectable viral load
Improves CD4+ T-cell counts, enhancing immune system performance
2. Chronic Hepatitis B
Effective in reducing HBV DNA levels in serum
Helps normalize liver enzymes and improve liver histology
Reduces the risk of cirrhosis and liver cancer over time
Dosage and Administration
The usual recommended dosage of TELAVINCE 300 is:
One tablet (300 mg) taken once daily, with or without food
For patients with renal impairment, dosage adjustments may be necessary depending on creatinine clearance levels
Always follow the prescribing physician’s recommendations for use, especially when used as part of a combination ART regimen.
Pharmacokinetics
Absorption: Rapidly absorbed after oral administration
Bioavailability: Approximately 25% when fasting; increased with food
Half-life: Approximately 17 hours, allowing for once-daily dosing
Excretion: Primarily via the kidneys through glomerular filtration and active tubular secretion
Advantages of TELAVINCE 300
Clinically Proven Efficacy
TELAVINCE 300 is backed by years of clinical data supporting its use as a first-line antiviral agent in global HIV and HBV treatment protocols.
Once-Daily Dosing
The convenience of a single daily dose significantly improves treatment adherence and simplifies long-term therapy.
Well-Tolerated Profile
TELAVINCE 300 is generally well tolerated in patients, with a manageable side effect profile.
Effective Viral Suppression
It helps maintain undetectable HIV RNA levels and significantly reduces HBV DNA, thus preventing disease progression.
Compatible with Combination Therapy
TELAVINCE 300 integrates easily into various combination regimens used in antiretroviral therapy, enhancing its flexibility in patient care.
Safety and Precautions
Renal Function Monitoring
Tenofovir is primarily excreted by the kidneys. Patients with pre-existing kidney conditions should be monitored regularly, and dose adjustments may be necessary.
Bone Mineral Density
Long-term use may be associated with reduced bone mineral density, particularly in older adults or those with risk factors for osteoporosis. Monitoring and supplementation may be advised.
Hepatic Exacerbations
Discontinuation of therapy in patients with chronic Hepatitis B may result in acute flare-ups of liver disease. Liver function should be monitored closely post-treatment.
Lactic Acidosis
Though rare, cases of lactic acidosis and hepatomegaly with steatosis have been reported. Patients presenting with unexplained fatigue, abdominal pain, or respiratory symptoms should be evaluated promptly.
Common Side Effects
Most adverse effects are mild and transient. These may include:
Nausea
Headache
Diarrhea
Fatigue
Dizziness
Abdominal discomfort
In rare cases, renal dysfunction, decreased bone density, or lactic acidosis may occur. Any persistent or severe symptoms should be reported to a healthcare provider.
Storage Conditions
Store below 30°C in a dry place
Protect from light and moisture
Keep out of reach of children
Presentation and Packaging
TELAVINCE 300 is available in:
Blister packs or HDPE bottles containing 30 tablets, providing a full month’s therapy
Each tablet is film-coated for ease of swallowing and optimal stability
Why Choose TELAVINCE 300?
High-quality formulation under stringent GMP guidelines
Affordable antiviral therapy for long-term management
Trusted by physicians and healthcare institutions
Flexible for use in both HIV and HBV treatment regimens
Excellent patient adherence due to convenient once-daily dosing
Conclusion
Tenofovir Disoproxil Fumarate 300 mg is a cornerstone therapy in the treatment of HIV-1 and chronic Hepatitis B, offering a reliable and scientifically validated option for long-term disease control. With proven antiviral efficacy, a favorable safety profile, and high patient compliance, TELAVINCE 300 continues to play a critical role in improving the quality of life for patients worldwide.
As part of a comprehensive treatment strategy, TELAVINCE 300 empowers healthcare professionals and patients to manage chronic viral infections with confidence, safety, and efficacy.
